HRMY

32.5901.18%
PA

Peter Anastasiou

Senior Executive VP & COO

Mr. Peter Anastasiou is Chief Operating Officer of Harmony Biosciences Holdings, Inc. from April 2026 and also serves as its Senior Executive Vice President. Mr. Anastasiou served as Chief Executive Officer at Capsida Biotherapeutics, Inc. since January 3, 2022 until November 2025 and served as its President and Director until November 2025. He serves as an Independent Director at Harmony Biosciences, LLC since 2023. He served as a Director of Harmony Biosciences Holdings, Inc. since November 05, 2023 until April 2026. He served as an Executive Vice President of North America at H. Lundbeck A/S since November 1, 2017. He served as President and Director at Lundbeck Seattle BioPharmaceuticals, Inc. since October 22, 20199. Mr. Anastasiou served as President of North America at H. Lundbeck A/S until November 1, 2017. As the President of Lundbeck's U.S. and Canadian business operations, Mr. Anastasiou has built organizations from the ground up. He served as Chief Commercial Officer at Lundbeck. He has significant leadership experience managing diverse organizations and bringing them together to achieve common goals. During his tenure at Lundbeck, Mr. Anastasiou held several progressive leadership positions, playing a pivotal role in developing and launching multiple products and building the company's cross-functional capabilities. Mr. Anastasiou serves on the Board of PhRMA and the global advisory Board for the Healthcare Businesswomen's Association. Prior to Lundbeck, Mr. Anastasiou held management roles at Neuronetics, Inc. Bristol-Meyers Squibb Company and Eli Lilly and Company. Mr. Anastasiou served as the Vice President of Marketing of Neuronetics, Inc. since April 10, 2006. Mr. Anastasiou joined Neuronetics from Bristol-Myers Squibb where he was a Director of the U.S. Marketing Team for Abilify(R), a leading antipsychotic medication. Prior to BMS, Mr. Anastasiou was at Eli Lilly where his responsibilities included the market preparations for the launch of Cymbalta(R), Lilly''s latest entry into the antidepressant marketplace. He holds an MBA from the Kelley School of Business at Indiana University and a B.A. in economics and management from Albion College.

Positions